
Medicine & Healthcare
By TrendScope Daily Team · November 22, 2026
Between early October and mid-November 2026, the US Food and Drug Administration cleared five separate cancer treatments — covering colon, rectal, prostate, head-and-neck and bladder cancers. None of these approvals made front-page news in India, but together they mark one of the busier stretches of oncology drug approvals in recent memory, and several of the underlying trial results are striking enough that patients and families dealing with these cancers should know what changed.
A quick note before the details: these are US FDA approvals, not Indian ones. Drugs cleared in the US typically go through a separate review by India’s Central Drugs Standard Control Organisation (CDSCO) before they become available here, which can take anywhere from several months to a few years. What follows is what each approval is, in plain language, and why oncologists are paying attention.
1. Tecentriq (atezolizumab) — stage 3 colon cancer
Approved: October 8, 2026. Tecentriq is an immunotherapy drug now approved for stage 3 colon cancer that has a specific genetic feature called mismatch repair deficiency (dMMR), to be given after surgery alongside two chemotherapy drugs. In the trial behind this approval (ATOMIC), patients who received Tecentriq alongside chemotherapy had roughly a 50% lower risk of their cancer returning or of death, compared with chemotherapy alone. An under-the-skin injectable version, Tecentriq Hybreza, was approved at the same time, which should make the drug quicker to administer in clinics.
2. Jemperli (dostarlimab) — locally advanced rectal cancer
Approved: October 19, 2026 (accelerated approval). Jemperli is approved for locally advanced rectal cancer (stage 2 or 3) that is dMMR or microsatellite instability-high (MSI-H) — the same genetic marker category as the Tecentriq approval above. What makes this one notable is the possibility, for some patients, of skipping surgery and radiation entirely. In the AZUR-1 trial, 47% of evaluable patients had no detectable tumour on exams and scans for at least 12 months after immunotherapy alone.
3. Talzenna plus Xtandi — metastatic prostate cancer
Approved: October 26, 2026. This is a combination of Talzenna (talazoparib) and Xtandi (enzalutamide) for hormone-sensitive metastatic prostate cancer in patients carrying HRR gene mutations such as BRCA1 or BRCA2 — the same genes linked to hereditary breast and ovarian cancer. In the TALAPRO-3 trial, the combination cut the risk of cancer progression or death by 52% compared with placebo plus Xtandi. The label carries a warning about low blood counts and blood cancers, so patients on this combination need regular blood tests.
4. Rybrevant Faspro — head and neck cancer
Approved: November 5, 2026 (accelerated approval). Rybrevant Faspro (amivantamab and hyaluronidase) is now approved for recurrent or metastatic head and neck squamous cell carcinoma, for patients whose cancer has progressed after platinum chemotherapy and PD-1/PD-L1 immunotherapy. It is not approved for HPV-associated oropharyngeal cancer specifically. This is the drug’s first approval outside lung cancer, and in the OrigAMI-4 trial, 42% of patients had their tumours shrink or disappear. Rash was the most common side effect, reported in 79% of patients.
5. Imfinzi plus Padcev — bladder cancer
Approved: November 13, 2026. Imfinzi (durvalumab) combined with Padcev (enfortumab vedotin) is now approved for muscle-invasive bladder cancer in patients who cannot or will not receive cisplatin-based chemotherapy. Patients receive both drugs before surgery to remove the bladder, then continue on Imfinzi alone afterward. In the VOLGA trial, this combination reduced the risk of cancer progression or death by 49% and the risk of death by 42%.
| Drug | Cancer type | Risk reduction (trial) | Approved |
|---|---|---|---|
| Tecentriq | Stage 3 colon cancer (dMMR) | ~50% lower recurrence/death risk | Oct 8, 2026 |
| Jemperli | Locally advanced rectal cancer (dMMR/MSI-H) | 47% had no detectable tumour at 12 months | Oct 19, 2026 |
| Talzenna + Xtandi | Metastatic prostate cancer (HRR mutation) | 52% lower progression/death risk | Oct 26, 2026 |
| Rybrevant Faspro | Head and neck squamous cell carcinoma | 42% had tumour shrinkage/disappearance | Nov 5, 2026 |
| Imfinzi + Padcev | Muscle-invasive bladder cancer | 49% lower progression/death risk | Nov 13, 2026 |
Why this cluster of approvals matters
Four of these five approvals lean on immunotherapy — drugs that help a patient’s own immune system recognise and attack cancer cells — either alone or paired with chemotherapy, hormone therapy or a second targeted drug. That pattern reflects where oncology research has been heading for several years: rather than one blockbuster drug, treatment is increasingly built around genetic markers (dMMR, MSI-H, HRR mutations) that identify which patients are most likely to benefit from a specific combination.
For patients and families, the practical takeaway is that a cancer diagnosis today comes with more biomarker testing than it used to, precisely because that testing is what determines eligibility for treatments like the ones above. If you or a family member has been diagnosed with one of these cancers, it is worth asking your oncologist whether biomarker testing (for dMMR, MSI-H or HRR mutations, depending on the cancer) has been done and what it showed.
This article is for general information and is not medical advice. Please consult a qualified doctor about your own health.
Sources: Approval dates, trial names and results reported by CURE Today, cross-referenced against the US FDA’s own oncology approval notifications at fda.gov.
Quick questions
Are these new cancer drugs available in India?
Not automatically. These are US FDA approvals. Drugs typically need a separate CDSCO review before they are approved for sale in India, which can take months to years depending on the drug.
What does dMMR or MSI-H mean?
They are genetic markers found in some tumours that make cancer cells easier for immunotherapy drugs to recognise and attack. Several of this fall’s approvals are specifically for patients whose tumours test positive for one of these markers.
Can immunotherapy alone replace surgery for rectal cancer?
For some patients with locally advanced, dMMR/MSI-H rectal cancer, the Jemperli trial found 47% had no detectable tumour on scans after a year of immunotherapy alone, without surgery or radiation. This does not apply to all rectal cancer patients, only this specific biomarker group, and the decision is made case by case with an oncologist.
Related on TrendScope Daily
- What is a tumor board? How cancer treatment gets decided
- Mounjaro fails CDSCO quality test in India: what it means
- Ayushman Bharat eligibility: who qualifies and how to apply
- More Medicine & Healthcare stories: browse the Medicine & Healthcare section
- All our health explainers: Health Explained hub
- Today’s full roundup: Trending Today in India: November 22, 2026